1956-21-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Pyridyl)-DL-alanine is used as a key intermediate in the synthesis of various pharmaceuticals, particularly in the development of anticancer drugs. Its antitumor properties make it a valuable component in the creation of novel therapeutic agents.
Used in Anticancer Applications:
3-(4-Pyridyl)-DL-alanine is used as an anticancer agent for its potential to target and inhibit the growth of cancer cells. Its antiviral properties also contribute to its effectiveness in combating cancer by limiting the spread of viruses that can contribute to the development of tumors.
Used in Neuroscience Research:
3-(4-Pyridyl)-DL-alanine is used as a research tool in the field of neuroscience to study its potential role in the regulation of neurotransmitters in the brain. This research could lead to the development of new treatments for neurological disorders and mental health conditions.
Used in Drug Synthesis:
3-(4-Pyridyl)-DL-alanine is used as a building block in the synthesis of various drugs, leveraging its versatile chemical structure to create new compounds with potential therapeutic benefits.

InChI:InChI=1/C8H10N2O2/c9-7(8(11)12)5-6-1-3-10-4-2-6/h1-4,7H,5,9H2,(H,11,12)

Upstream product

• 108-89-4 picoline 
• 1353886-58-4 ethyl 3-(4-pyridinyl)-2-hydroxyimino propionate 
• 102913-23-5 (4Z)-2-methyl-4((pyridin-4-yl)methylene)oxazol-5(4H)-one 
• 872-85-5 pyridine-4-carbaldehyde 
• 111759-54-7 N-acetyl-4 pyridylalanine 
• 37535-49-2 (S)-2-amino-3-(pyridin-4-yl)propanoic acid 
• 84228-93-3 3-(pyridin-4-yl)acrylic acid 
• 73870-24-3 4-bromomethyl pyridine hydrobromide 
• 1822-51-1 4-picolylchloride hydrochloride 
• 89662-45-3 diethyl 2-(acetylamino)-2-(4-pyridinylmethyl)-malonate 

Downstream Products

• 33560-92-8 2-benzoylamino-3-[4]pyridyl-propionic acid 
• 79601-07-3 2-(4-Chloro-benzylamino)-3-pyridin-4-yl-propionic acid 
• 104331-26-2 rac-2-Decarboxybetalaminsaeure-imin 
• 1397815-20-1 C₂₄H₂₂N₂O₄ 
• 169555-95-7 (S)-N-(9-fluorenylmethoxycarbonyl)-β-(4-pyridyl)alanine 
• 746672-87-7 Fmoc-[2-amino-4-(pyridine-4-yl)butanoic acid] 

Relevant academic research and scientific papers

Phenylalanine ammonia lyase catalyzed synthesis of amino acids by an MIO-cofactor independent pathway

Phenylalanine ammonia lyases (PALs) belong to a family of 4-methylideneimidazole-5-one (MIO) cofactor dependent enzymes which are responsible for the conversion of L-phenylalanine into trans-cinnamic acid in eukaryotic and prokaryotic organisms. Under conditions of high ammonia concentration, this deamination reaction is reversible and hence there is considerable interest in the development of PALs as biocatalysts for the enantioselective synthesis of non-natural amino acids. Herein the discovery of a previously unobserved competing MIO-independent reaction pathway, which proceeds in a non-stereoselective manner and results in the generation of both L- and D-phenylalanine derivatives, is described. The mechanism of the MIO-independent pathway is explored through isotopic-labeling studies and mutagenesis of key active-site residues. The results obtained are consistent with amino acid deamination occurring by a stepwise E1cB elimination mechanism. All manner of things: A competing MIO-independent (MIO=4-methylideneimidazole-5-one) reaction pathway has been identified for phenylalanine ammonia lyases (PALs), which proceeds in a non-stereoselective manner, resulting in the generation of D-phenylalanine derivatives. The mechanism of D-amino acid formation is explored through isotopic-labeling studies and mutagenesis of key active-site residues.

Chemoenzymatic routes to enantiomerically pure 2-azatyrosine and 2-, 3- and 4-pyridylalanine derivatives

Enantiomerically pure 2-, 3- or 4-pyridylalanine (pya) and 2-azatyrosine (azatyr) are known to present various biological activities. After incorporation into appropriate peptide sequences, these heterocyclic non natural α-amino acids could behave as new substrates or inhibitors of elastase from Pseudomonas aeruginosa. This enzyme is known to be involved in nosocomial infections and infections related to the cystic fibrosis disease. New efficient chemoenzymatic preparations of those compounds using α-chymotrypsin (α-CT) are presented. Springer-Verlag 2011.

Enhanced reduction of C-N multiple bonds using sodium borohydride and an amorphous nickel catalyst

Amorphous nickel powder (Ni0) was utilised as a catalyst under mild, aqueous, basic conditions for enhancing the sodium borohydride-mediated reduction of C-N multiple bonds such as oximes, imines, hydrazones and nitriles to produce the corresponding amines in good to excellent yields.